Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1991 Jan 15;144(2):161–168.

Screening for hypercholesterolemia among Canadians: how much will it cost?

S A Grover 1, L Coupal 1, R Fahkry 1, S Suissa 1
PMCID: PMC1453000  PMID: 1986828

Abstract

OBJECTIVE: To determine the cost of screening all Canadians aged 30 years or more without coronary heart disease (CHD) for hypercholesterolemia. DATA SOURCES: The expected results of initial screening of the serum cholesterol level were estimated on the basis of 1986 Canadian census data and the 1978 Canada Health Survey. The results of repeat testing were estimated on the basis of data from the Lipid Research Clinics Prevalence Study. Lipid profile results were extrapolated from tests at the Montreal General Hospital's clinical chemistry laboratory. Laboratory costs and primary care practitioner costs were provided by the Canadian Society of Clinical Chemists and provincial fee schedules respectively. MAIN RESULTS: Among 12,479,356 Canadians free of CHD 48.7% would be identified as being at high risk, 4.8% would be identified as being at moderate risk, and 46.6% would be reassured that their lipid risk for CHD was low. The total cost of implementing the program in the first year would be $432 million to $561 million ($325 million for laboratory tests and $107 million to $236 million for visits to primary care practitioners). CONCLUSION: The substantial cost of implementing a nationwide screening program must be weighed against the expected benefits to ensure that the final result is both practical and economically feasible.

Full text

PDF
161

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson K. M., Castelli W. P., Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987 Apr 24;257(16):2176–2180. doi: 10.1001/jama.257.16.2176. [DOI] [PubMed] [Google Scholar]
  2. Elford R. W., Yeo M. The impact of preventive cardiology on coronary artery disease. CMAJ. 1988 Oct 15;139(8):719–724. [PMC free article] [PubMed] [Google Scholar]
  3. Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245. doi: 10.1056/NEJM198711123172001. [DOI] [PubMed] [Google Scholar]
  4. Horlick L. Hypercholesterolemia. CMAJ. 1989 Jan 15;140(2):176–176. [PMC free article] [PubMed] [Google Scholar]
  5. Jacobs D. R., Jr, Barrett-Connor E. Retest reliability of plasma cholesterol and triglyceride. The Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1982 Dec;116(6):878–885. doi: 10.1093/oxfordjournals.aje.a113490. [DOI] [PubMed] [Google Scholar]
  6. Kannel W. B. Cholesterol and risk of coronary heart disease and mortality in men. Clin Chem. 1988;34(8B):B53–B59. [PubMed] [Google Scholar]
  7. Kinosian B. P., Eisenberg J. M. Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia. JAMA. 1988 Apr 15;259(15):2249–2254. doi: 10.1001/jama.259.15.2249. [DOI] [PubMed] [Google Scholar]
  8. Langner N. R., Hasselback P. D., Dunkley G. C., Corber S. J. Attitudes and practices of primary care physicians in the management of elevated serum cholesterol levels. CMAJ. 1989 Jul 1;141(1):33–38. [PMC free article] [PubMed] [Google Scholar]
  9. Little J. A. A physician's guide to lipoprotein metabolism. CMAJ. 1989 Sep 15;141(6):573–573. [PMC free article] [PubMed] [Google Scholar]
  10. Little J. A., Horlick L. Consensus reports: implications for the management of hypercholesterolemia and for future research. CMAJ. 1989 Feb 15;140(4):369–370. [PMC free article] [PubMed] [Google Scholar]
  11. MacLean D. R. The public health approach: the Nova Scotia experience. Canadian Atherosclerosis Society. CMAJ. 1989 Oct 15;141(8):797–797. [PMC free article] [PubMed] [Google Scholar]
  12. Oster G., Epstein A. M. Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine. JAMA. 1987 Nov 6;258(17):2381–2387. [PubMed] [Google Scholar]
  13. Semenciw R. M., Morrison H. I., Mao Y., Johansen H., Davies J. W., Wigle D. T. Major risk factors for cardiovascular disease mortality in adults: results from the Nutrition Canada Survey cohort. Int J Epidemiol. 1988 Jun;17(2):317–324. doi: 10.1093/ije/17.2.317. [DOI] [PubMed] [Google Scholar]
  14. Sempos C., Fulwood R., Haines C., Carroll M., Anda R., Williamson D. F., Remington P., Cleeman J. The prevalence of high blood cholesterol levels among adults in the United States. JAMA. 1989 Jul 7;262(1):45–52. [PubMed] [Google Scholar]
  15. Taylor W. C., Pass T. M., Shepard D. S., Komaroff A. L. Cholesterol reduction and life expectancy. A model incorporating multiple risk factors. Ann Intern Med. 1987 Apr;106(4):605–614. doi: 10.7326/0003-4819-106-4-605. [DOI] [PubMed] [Google Scholar]
  16. Weinstein M. C., Stason W. B. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health. 1985;6:41–63. doi: 10.1146/annurev.pu.06.050185.000353. [DOI] [PubMed] [Google Scholar]
  17. Wones R. G., Kerman K. M., Hissa D. C., Meloy N., Stein E. A. Comparisons of referral criteria for public screening of blood cholesterol levels. Public Health Rep. 1989 Sep-Oct;104(5):425–432. [PMC free article] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES